As part of our ongoing commitment to supporting the young musicians who attend the Klein Competition each year, we continue to offer our semifinalists accomodations with our friends and musical community in the San Francisco Bay Area during their stay. As a Klein Competition host, you will provide one of our semifinalists with housing, occasional meals, and hospitality from Tuesday, June 10, through Sunday, June 15. You may also choose to provide transportation. Hosting a Klein Competition Semifinalist is a wonderful way to get a glimpse into the personality, artistry, and musical excellence that each brings to our competition. Hosts share a wide range of experiences including attending the competition, competition dinners and receptions, and an unforgettable range of interactions with our young stars. Please contact our office if you are interested, for example, carvedilol vs metoprolol. A. J. W. Branten et al. beta-adrenoceptor blocking drugs. J Hem 1989; 2: 237S240S Hannedouche T, Brouard R, Godin M, Kleinknecht D, Paillard F, Grunfeld JP. Chronic effects of tertatolol on renal function in hypertensive patients with mild chronic renal failure. Nephrol Dial Transplant 1991; 6: 252256 Guillet C. Overview of novel renal properties of tertatolol. Cardiology 1993; 83 [Suppl 1]: 6469 Nitenberg A, Prost J-F, Joussen J-M, Blanchet F, DutrayDupagne C. Selective infusion of tertatolol into the renal artery induces a local vasodilator effect in humans. J Hem 1989; 2: 228S232S Sluiter HE, Wetzels JF, Huysmans FThM, Koene RAP. The natriuretic effect of the dihydropyridine calcium antagonist felodipine: a placebo-controlled study involving intravenous angiotensin II in normotensive volunteers. J Cardiovasc Pharmacol 1987; 10 [Suppl 10]: S154S161 Gifford Jr. RW, Borazanian A. Traditional first-line therapy Overview of medical benefits and side effects. Hypertension 1989; 13 [Suppl I ]: I-II9I-124 Curtis JJ. Management of hypertension after transplantation. Kidney Int 1993; 44 [Suppl 43]: S45S49 Verbeuren TJ, Herman AG. Pharmacological features of the vasodilation induced by tertatolol in isolated perfused rat. J Hem 1989; 2: 219S222S Verbeuren TJ, Mennecier P, Laubie M. 5-Hydroxytryptamineinduced vasodilation in the isolated perfused rat kidney are endothelial 5-HT1A receptors involved? Eur J Pharmacol 1991; 201: 1727 Bennet WM. The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 1995; 43 [Suppl 1]: S3S7 Leeman M, Vereerstraeten P, Uytdenhoef M, Degaute JP. Systemic and renal hemodynamic responses to carvedilol and metoprolol in hypertensive renal transplant patients. J Cardiovasc Pharmacol 1993; 22: 706710 Sorensen SS, Skovbon H, Eiskjaer H, Thomsen K, Pedersen EB. Effect of felodipine on renal hemodynamics and tubular sodium handling in cyclosporine-treated renal transplant recipients. Nephrol Dial Transplant 1992; 7: 6978 Pesavento TE, Jones PA, Julian BA, Curtis JJ Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Soc Nephrol 1995; 7: 831835 Huysmans FThM, Heusden FHJA, Wetzels JFM, Hoitsma AJ, Koene RAP. Antihypertensive effect of beta-blockade in renal transplant recipients with or without host kidneys. Transplantation 1988; 46: 234237 Huysmans FThM, Hoitsma AJ, Koene RAP. Factors determining the prevalence of hypertension after renal transplantation. Nephrol Dial Transplant 1987; 2: 3438 Curtis JJ, Diethelm AG, Luke RG, Welchel JD, Jones P. Benefits of removal of native kidneys after renal transplantation. Lancet 1985, ii: 739742 Laragh JH. Issues, goals, and guidelines in selecting first-line drug therapy for hypertension. Hypertension 1989; 13 [Suppl 1]: I-103-I-112 and cutivate.

Table 2. Pre-Hospital Assessment Review Results Record Review Item Number Total Percent Respiratory Rate Documented 80 90 89% Initial Pulse Oximetry Documented 89 90 99% If Documented, Pulse Oximetry 92% 16 83 Emergency Department Assessment. Assessment of pediatric respiratory distress patients was recorded at high levels for patient weight 92% ; , respiratory effort 90% ; , breath sounds 89% ; , respiratory rate 99% ; , pulse oximetry 93% ; , and mental status 91% ; , as shown in Table 3. Recorded less often were skin color 75% ; , blood pressure 55% ; , and patient height 23 and cyproheptadine.

5: 30 - 6: Our Paleolithic Heritage and Implications for Health and Disease Dr. Dag Viljen Poleszynski In his second session, Dr. Poleszynski will discuss how genetic traits have evolved through the interaction of the human genome with the environment and how the ultimate basis for most diet-related disease has resulted from evolutionary discordance between our ancient genome and "new" foods. 6: 20 6: Question & Answer Session. The four american certificates were written by shelley l beckman, phd, megan shields, md, forest tennant, md and alfonso poredes, md, shelley beckman lacks medical education and the main sphere of interest of megan shields is chlorated pesticides and diamicron and carvedilol, for instance, carvedliol dosing. Packer M. Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, and Shusterman NH. The effect of carvedilkl on morbidity and mortality in patients with chronic heart failure. US Cxrvedilol Heart Failure Study Group. N Eng J Med 334: 134955, 1996. Carvedilol is a cardiovascular drug currently ABSTRACT used for the treatment of hypertension. Clinical studies have recently demonstrated efficacy in angina and congestive heart failure. Recently, carvedilo has been shown to attenuate oxygen free radical-initiated lipid peroxidation and to inhibit vascular smooth muscle mitogenesis induced by a wide variety of growth factors. These rmdings are of interest since smooth muscle proliferation and abnormal lipid metabolism are proposed to play an important role in the pathogenesis of atherosclerotic plaque formation and in development of stenotic lesions following vascular iD, ury by balloon angioplasty and coronary artery bypass grafting. On the basis of these observations, the antiproliferative actions of carvedilol have been explored in detail. In human cultured pulmonary artery vascular smooth muscle cells, carvedilol 0.1-10 FM ; produced a concentration-dependent inhibition of the mitogenesis stimulated by platelet-derived growth factor, epidermal growth factor, thrombin, and serum, with ICso values ranging from 0.3 to 2.0 #sM. Carveedilol also produced a concentrationdependent inhibition of vascular smooth muscle cell migration induced by platelet-derived growth factor, with an IC5. value of 3 FM. The extensive neointimal formation that occurs following balloon angioplasty of rat carotid arteries was markedly attenuated by carvedilol 1 mg kg, i.p.; twice daily starting 3 days before angioplasty and continuing until 14 days after angioplasty ; . Quantitative image analysis demonstrated that carvedilol reduced the neointimal growth following angioplasty by 84% without altering either medial or adventitial cross-sectional areas. These observations indicate that carvedilol may also be effective in the treatment of pathological disorders principally associated with abnormal vascular smooth muscle growth, such as atherosclerosis and acute vascular wail injury induced by angioplasty or coronary artery bypass gng and diclofenac. The TAF Education Fund [TAFEF] is a non-profit charitable organization dedicated to combating fraud against the Federal Government through the promotion and use of the qui tam provisions of the False Claims Act [FCA]. Qui tam is a unique mechanism in the Act that allows persons and entities with evidence of fraud against federal programs or contracts to bring suit on behalf of the government. Based in Washington, DC, TAFEF serves to inform and educate the general public, the legal community, and other interested groups about the FCA and its qui tam provisions. In furtherance of its mission, TAFEF provides information and other assistance to qui tam plaintiffs and their counsel, publishes the False Claims Act and Qui Tam Quarterly Review and other educational materials, and files amicus curiae briefs on important legal and policy issues affecting the Act. TAFEF maintains a comprehensive FCA library for public use and a staff of lawyers and other professionals who are available to assist anyone interested in the False Claims Act and qui tam. For more information see taf. Prescription drugs are those drugs that are only legally available with a doctor's prescription. They are used to relieve pain and to treat a variety of medical conditions. Although most people who take prescription medications use them responsibly, the non-medical use of prescription drugs is a serious public health concern and can lead to drug abuse and dependence that is characterized by compulsive drug seeking and use.25.

Due to biological diversity in aquatic environments, it is difficult to offer general conclusions about the mixtures of PPCPs found in surface waters today. Although limited data does exist for the potential of acute toxicity, this data may cloud our vision as to the subtle effects. There is plenty of evidence to suggest that this is a question of potential concern. Aquatic environments are a concern because aquatic organisms in this environment are subject to continual exposure.1 Interestingly, our regulatory system has not been designed to assess the potential risk. The Federal Drug Administration FDA ; requires Environmental Assessments EA ; under the National Environmental Policy Act of 1969 NEPA ; , and the specifics for drug applications are set forth in "Guidance for Industry Environmental Assessment of Human Drug and Biologics Application."9 The EA is only required if the expected concentration exceeds 1 part per billion ppb ; . This does not take into account the cumulative effect of multiple drugs of similar type, each of which may be at a concentration less than 1 ppb, in the environment. In Europe, the European Commission-Pharmaceuticals and Cosmetics EEC ; responsible for regulating this process is somewhat more comprehensive. The concern is primarily acute and chronic effects as measured by traditional toxicity tests. Though provision is made for environmental effects other then toxicity, such as behavior or environmental impact, the effect must have significant intensity to be considered important. Again, this system is inadequate in assessing the effects of a variety of different PPCP compounds, many of which may act in the same or a different manner. The next section of this article reviews evidence for the ecological effects of general categories of pharmacological agents. The list of medications that have not been evaluated is long. For more information, please refer to the EPA website dedicated to Pharmaceuticals in the Environment : teleosis epa ppcp.

Candesartan, for heart failure, 1, 3t Capecitabine, for cancer chemotherapy, 57t, 58 Capoten. See Captopril Captopril, for heart failure, 3t Carbamazepine for bipolar disorder, 40, 41t pregnancy and, 42 Carbatrol. See Carbamazepine Carvedilol, for heart failure, 2, 3t Cefizox. See Cephalosporins Cefobid. See Cephalosporins Cefotan. See Cephalosporins Celexa. See Citalopram Cephalosporins, for surgical prophylaxis, 83, 84t, 85t Ceralyte. See Rehydration salts Cetuximab, for cancer chemotherapy, 57, 58 Charcoal, activated, for treatment of overdose, 61, 63, 64 Chicken pox. See Varicella Chloral hydrate, for insomnia, 6 Chloroquine, for malaria, 30, 31t Chlorpromazine, for psychotic disorders, 43, 44t Cholera, vaccine for, 25 Cipro, Cipro XR. See Ciprofloxacin Ciprofloxacin for surgical prophylaxis, 83, 85t for travelers' diarrhea, 29t Cisplatin, for cancer chemotherapy, 55, 56t, 58 Citalopram, for depression, 36t Claforan. See Cephalosporins Cleocin. See Clindamycin Clindamycin, for surgical prophylaxis, 83, 85t Clomipramine, for anxiety disorders, 39t, 40 Clonazepam for anxiety disorders, 39, 40 for insomnia, 7t Clozapine for bipolar disorder, 43 for psychotic disorders, 43, 44t Clozaril. See Clozapine Cognitive behavioral therapy CBT ; for anxiety disorders, 40 for insomnia, 9 for irritable bowel syndrome, 15 Colace. See Docusate Combivir, for HIV infection, 70t Concerta. See Methylphenidate MPH ; Constipation, irritable bowel syndrome and, 12, 13t Coreg. See Czrvedilol Cozaar. See Losartan Crixivan. See Indinavir Cutter Advanced. See Picaridin Cymbalta. See Duloxetine Cytomel. See Liothyronine LT3. Cefaclor but is not an analgesic ; and in mania. May cause drowsiness, blurred vision, dizziness and gastro-intestinal upsets. Skin rashes and adverse effects on the liver and bone marrow are relatively common. Coma with convulsions in overdosage. No antidote; supportive treatment only. Carbaryl. Anticholinesterase. Used topically as an insecticide e.g. for lice ; . Carbenicillin. PENICILLIN antibiotic, particularly active against Gram-negative bacteria especially Pseudomonas and Proteus. Adverse effects as for BENZYLPENICILLIN. Carbenoxolone. Used in treatment of gastric and duodenal ulcers and for mouth ulcers. Has ALDOSTERONE-like actions. Adverse effects include oedema, hypertension, hypokalaemia and muscle pain. Carbidopa. Dopamine decarboxylase inhibitor used with LEVODOPA in fixed dose combinations as CO-CARELDOPA. Similar actions to BENSERAZIDE. Carbimazole. Depresses formation of thyroid hormone. Used in treatment of hyperthyroidism. Adverse effects include allergic rashes, nausea, diarrhoea, blood abnormalities and keratitis. Carbinoxamine. Antihistamine, actions similar to PROMETHAZINE. with Carmellose r ; . Cellulose derivative employed in artificial tears and as a pharmaceutical aid in drug formulations. Carmustine. Intravenous cytotoxic, inactivates DNA, RNA and several enzymes. Crosses the blood-brain barrier, thus useful for brain tumours as well as certain other neoplastic diseases. Rapidly degraded from the parent drug to active metabolites. Adverse effects include nausea, vomiting, burning sensation at injection site, renal and hepatic damage, and delayed bone marrow suppression. Carteolol. Beta-adrenoceptor blocking drug used in prevention of angina. Actions and adverse effects similar to PROPRANOLOL. Carvedilol. Nonselective beta-adrenoceptor antagonist with alpha-antagonist activity. Used as prophylaxis of stable angina and in treatment of hypertension where its effects are similar to PROPRANOLOL. Also used for chronic cardiac failure. May be used with care for patients with chronic heart failure. Adverse effects include dizziness, headache, gastro-intestinal upset, postural hypotension and pain in extremeties. Cascara. Purgative from bark of buckthorn tree. Stimulates gut movement via the nerve plexus in the large bowel wall. Produces reddish-brown discolouration of urine and may cause excessive catharsis. Excreted in milk of lactating mothers and may cause diarrhoea in infants. Prolonged use causes black pigmentation in colon melanosis coli ; . Castor oil. Purgative, with action upon small intestine as well as large intestine useful when prompt evacuation is required e.g. before bowel X-rays ; . Chronic use not recommended as it causes reduced absorption of nutrients. Also used topically on skin for its emollient effect. Cefaclor. Cephalosporin antibiotic. Orally active and has wider range of activity than earlier drugs of that group. Actions, uses and adverse effects similar to CEPHALOTHIN and cilostazol.